Form 10-K Intellia Therapeutics, For: Dec 31
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq fall, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Evercore ISI Reiterates $70 PT on Intellia Therapeutics (NTLA), 'Year of P3 execution'
February 23, 2024 9:27 AM ESTEvercore ISI analyst Liisa Bayko reiterated an Outperform rating and $70.00 price target on Intellia Therapeutics (NASDAQ: NTLA).
The analyst comments "2024 will be a year of execution for NTLA with P3 for NTLA-2001 in ATTR-CM ongoing while preparing P3 for ATTR-PN and HAE. P3 MAGNITUDE study for NTLA-2001 in ATTR-CM kicked off end of last year and will dose the first patient in 1Q. The trial size is slightly greater than that of HELIOS-B (ALNY). We estimate enrollment to complete around year-end 2024 and topline readout in 2H27.... More
Citi on Intellia Therapeutics (NTLA): 'we believe that NTLA-2001 might find its home as a niche offering'
February 23, 2024 9:25 AM ESTCiti analyst David Lebowitz reiterated a Neutral rating and $31.00 price target on Intellia Therapeutics (NASDAQ: NTLA).
The analyst comments "Following competitor Alnylams HELIOS-B updates (HERE), mgt. remains confident in the event-driven design of NTLA-2001s Ph3 MAGNITUDE trial. While there are no planned... More
Goldman Sachs Downgrades Intellia Therapeutics (NTLA) to Neutral, 'A quieter 2024 catalyst path'
February 23, 2024 9:19 AM ESTGoldman Sachs analyst Salveen Richter downgraded Intellia Therapeutics (NASDAQ: NTLA) from Buy to Neutral with a price target of $32.00.
The analyst comments "NTLA reported 4Q EPS and reiterated the near-term catalyst path for NTLAs in vivo CRISPR gene-edited therapies, which include: 1) longer-term Ph1 data from NTLA-2001 in ATTR-cardiomyopathy (ATTR-CM) and... More
